The effects of losartan and fosinopril in hypertensive type 2 diabetic patients
| Autor: | Akif Sahin, H. Önder Ersöz, Cihangir Erem, Feyyaz Ozdemir, Halil Kavgaci |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Adult
Blood Glucose Male medicine.medical_specialty Time Factors medicine.drug_class Endocrinology Diabetes and Metabolism Urology Renal function Angiotensin-Converting Enzyme Inhibitors Blood Pressure Diabetic angiopathy Losartan Diabetic nephropathy Electrolytes Endocrinology Diabetes mellitus Fosinopril Internal medicine Diet Diabetic Internal Medicine Medicine Humans Hypoglycemic Agents Insulin Aspartate Aminotransferases Antihypertensive drug Antihypertensive Agents Dose-Response Relationship Drug business.industry Alanine Transaminase General Medicine Middle Aged medicine.disease Lipids Diabetes Mellitus Type 2 Hypertension Microalbuminuria Female business Diabetic Angiopathies medicine.drug |
| Zdroj: | Diabetes research and clinical practice. 58(1) |
| ISSN: | 0168-8227 |
| Popis: | The aim of this study is to evaluate the effects of losartan on blood pressure (BP), creatinine clearance (Ccr) and urinary albumin excretion (UAE), and to assess metabolic parameters in comparison with ACEI. Thirty-three type 2 diabetic hypertensive patients were enrolled in the study. Twenty patients were randomized to receive 50 mg/day losartan and 13 patients to 10 mg/day fosinopril. Patients were studied at baseline and after 1 and 6 months. BP was significantly decreased in both groups at the end of the 1st and 6th month to a similar extent. Ccr had fallen in both groups at the end of 1st and 6th months. The effect of each drug on Ccr was similar (64.2+/-70.6 and 42.8+/-53.8 ml/min, respectively, NS). In the subgroup with microalbuminuria at baseline, UAE rate was lower in both groups at the end of the 1st and 6th months. However, when compared with the end of 1st month, the antiproteinuric effect of losartan was slightly decreased at the end of 6th month. Metabolic parameters did not change with either drug. Both drugs were well tolerated. Thus the antihypertensive effects of the two drugs were comparable. In conclusion, this study confirms the efficacy and safety of losartan as an antihypertensive drug in diabetic patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect